Peptides Academy
Insulin Aspart
NovoLog / NovoRapid / Fiasp
Insulin aspart is a rapid-acting analog insulin in which a single amino acid on the B-chain (proline at position B28) is replaced by aspartic acid. As with insulin lispro, this change does not alter the hormone's action at the receptor, but the negatively charged aspartic acid reduces the tendency of insulin molecules to associate into hexamers, so the drug dissociates into absorbable monomers faster after a subcutaneous injection. The effect is a mealtime insulin with a rapid onset (about 15 minutes) and a short duration that can be dosed right around meals, matching the glucose surge from eating more closely than human Regular insulin. Insulin aspart is a mainstay bolus insulin in basal-bolus regimens and in insulin pumps for type 1 and type 2 diabetes. An ultra-rapid formulation, Fiasp, adds niacinamide and other excipients to accelerate early absorption, allowing dosing at the start of a meal or shortly after. Insulin aspart is a prescription medicine, and like every insulin its principal risk is hypoglycemia; because it acts quickly, coordination with food intake matters. It provides mealtime coverage only and must be combined with a basal insulin (or a pump's basal delivery) for full 24-hour control. It is used under medical supervision and is not a performance-enhancing or wellness product.
Specifications
| Dose Range | U-100 |
| Origin / Manufacturer | Recombinant analog (B28 Asp substitution; yeast) |
| Regulatory Status | FDA-approvedEMA-approved |
| Active Components | Insulin aspart |
| Storage | Refrigerate unopened; in-use per label |
| Form Factor | Subcutaneous injection (pen/vial); pump-compatible |
Frequently Asked Questions
Reviewed by
Clinical Research Review Board
Pharmacology & Endocrinology Review
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
Insulin Degludec
Tresiba
An ultra-long-acting basal insulin: a fatty-acid tail makes it form long chains of multihexamers under the skin that release insulin very slowly, giving an exceptionally flat profile lasting well beyond 24 hours with flexible dosing timing.
Insulin Glargine
Lantus / Toujeo / Basaglar
A long-acting basal analog insulin engineered to precipitate under the skin and release slowly, giving roughly 24-hour, relatively flat background glucose coverage from a once-daily injection.
Human Insulin (Regular / NPH)
Humulin / Novolin
The archetypal peptide-hormone medicine: a 51–amino-acid two-chain hormone that lowers blood glucose. Recombinant "human" insulin comes as short-acting Regular and intermediate-acting NPH, the backbone of insulin therapy for a century.
Insulin Lispro
Humalog / Admelog / Lyumjev
A rapid-acting analog insulin: swapping two B-chain amino acids stops the molecules from clumping, so it is absorbed and acts faster than human Regular insulin — designed to be taken right at mealtimes.